dermaPACE® Phase III Trial Results Announced
View Technology Details, Study Design and 24-Week Top-Line Safety and Efficacy Results of SANUWAVE’s Randomized,
Double-blinded, Sham-controlled, Pivotal Clinical Trial
View Technology Details, Study Design and 24-Week Top-Line Safety and Efficacy Results of SANUWAVE’s Randomized,
Double-blinded, Sham-controlled, Pivotal Clinical Trial
News
May 14, 2012 - SANUWAVE Reports First Quarter Financial Results
May 8, 2012 - SANUWAVE Receives Conditional Approval from the FDA on Clinical Trial Plan for dermaPACE
Apr 3, 2012 - SANUWAVE's dermaPACE Shown to Improve Skin Flap Survival
May 14, 2012 - SANUWAVE Reports First Quarter Financial Results
May 8, 2012 - SANUWAVE Receives Conditional Approval from the FDA on Clinical Trial Plan for dermaPACE
Apr 3, 2012 - SANUWAVE's dermaPACE Shown to Improve Skin Flap Survival
About SANUWAVE
A pioneer in the field of regenerative medicine, SANUWAVE specializes in the development and commercialization of
non-invasive, biological response activating devices based on the PACE® Technology platform.
Learn more about ESWT and PACE Science
A pioneer in the field of regenerative medicine, SANUWAVE specializes in the development and commercialization of
non-invasive, biological response activating devices based on the PACE® Technology platform.
Learn more about ESWT and PACE Science